Neuroprotective role of liver growth factor "LGF" in an experimental model of cerebellar ataxia

• Published in: International journal of molecular sciences 2014-10, Vol.15 (10), p.19056-19073
• Main Authors: Calatrava-Ferreras, Lucía, Gonzalo-Gobernado, Rafael, Reimers, Diana, Herranz, Antonio S, Jiménez-Escrig, Adriano, Díaz-Gil, Juan José, Casarejos, María José, Montero-Vega, María Teresa, Bazán, Eulalia
• Format: Article
• Language: English
• Subjects: Animals; Antigens, Nuclear - metabolism; Bilirubin - pharmacology; Brain; Calbindins - metabolism; Cell Differentiation - drug effects; Cerebellar Ataxia - drug therapy; Cerebellar Ataxia - metabolism; cerebellar ataxias; Cerebellum - drug effects; Cerebellum - metabolism; Disease Models, Animal; Female; GABA; gamma-Aminobutyric Acid - metabolism; glutamate; Glutamic Acid - metabolism; liver growth factor; Microglia - drug effects; Microglia - metabolism; Nerve Tissue Proteins - metabolism; Neurobiology; Neurons - drug effects; Neurons - metabolism; neuroprotection; Neuroprotective Agents - pharmacology; neuroregeneration; Neurotransmitters; Protein expression; Proto-Oncogene Proteins c-bcl-2 - metabolism; Pyridines - pharmacology; Rats; Rats, Sprague-Dawley; Serum Albumin - pharmacology; Serum Albumin, Human
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms151019056

Cerebellar ataxias (CA) comprise a heterogeneous group of neurodegenerative diseases characterized by a lack of motor coordination. They are caused by disturbances in the cerebellum and its associated circuitries, so the major therapeutic goal is to correct cerebellar dysfunction. Neurotrophic factors enhance the survival and differentiation of selected types of neurons. Liver growth factor (LGF) is a hepatic mitogen that shows biological activity in neuroregenerative therapies. We investigate the potential therapeutic activity of LGF in the 3-acetylpiridine (3-AP) rat model of CA. This model of CA consists in the lesion of the inferior olive-induced by 3-AP (40 mg/kg). Ataxic rats were treated with 5 µg/rat LGF or vehicle during 3 weeks, analyzing: (a) motor coordination by using the rota-rod test; and (b) the immunohistochemical and biochemical evolution of several parameters related with the olivo-cerebellar function. Motor coordination improved in 3-AP-lesioned rats that received LGF treatment. LGF up-regulated NeuN and Bcl-2 protein levels in the brainstem, and increased calbindin expression and the number of neurons receiving calbindin-positive projections in the cerebellum. LGF also reduced extracellular glutamate and GABA concentrations and microglia activation in the cerebellum. In view of these results, we propose LGF as a potential therapeutic agent in cerebellar ataxias.